Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Capillary Electrophoresis Genetic Analyzers Introduced for Clinical Use

By LabMedica International staff writers
Posted on 02 Jun 2009
A new series of electrophoresis genetic analyzers is intended for clinical use. More...
The analyzers will be launched in specific countries within the European Union.

The 3500 Dx A platforms provide state-of-the-art advancements in CE sequencing systems, setting new standards for throughput, data quality, and ease-of-use. These analyzers are intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility.

The 3500 series (for research only) and 3500 Dx series were introduced by Applied Biosystems (Foster City, CA, USA) a division of Life Technologies Corporation. The new genetic analyzers provide an integrated solution that combines the instrument with Applied Biosystems reagents, consumables, software, service and support. Scientists are using the technology to study the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other disorders.

The system and accessories comply with the European Union in vitro diagnostic (IVD) medical devices directive 98/79/EC. Commercial launch of the 3500 Dx series systems is anticipated in August 2009.

Life Technologies Corporation, a global biotechnology tools company, was formed by a merger between Applied Sciences and Invitrogen (Carlsbad, CA, USA) in November 2008.

Related Links:
Applied Biosystems
Life Technogies Corp


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.